These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 24521857)

  • 1. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
    Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
    PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
    Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
    Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine cancer. Closing the GAPP on predicting metastases.
    Eisenhofer G; Tischler AS
    Nat Rev Endocrinol; 2014 Jun; 10(6):315-6. PubMed ID: 24686203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
    Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
    Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
    Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
    Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
    Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
    J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
    Wang LL; Wei XJ; Zhang QC; Li F
    Ann Diagn Pathol; 2022 Oct; 60():151981. PubMed ID: 35660808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of clinical and pathological characteristics of retroperitoneal paraganglioma and associated prognostic factors.
    Chun C; Song L; Xu G; Shi Q; Li F; Jia X
    J Surg Oncol; 2024 Jul; 130(1):47-55. PubMed ID: 38864273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MITOCHONDRIA: Succinate dehydrogenase subunit B-associated phaeochromocytoma and paraganglioma.
    Dona M; Neijman K; Timmers HJLM
    Int J Biochem Cell Biol; 2021 May; 134():105949. PubMed ID: 33609747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
    Benn DE; Croxson MS; Tucker K; Bambach CP; Richardson AL; Delbridge L; Pullan PT; Hammond J; Marsh DJ; Robinson BG
    Oncogene; 2003 Mar; 22(9):1358-64. PubMed ID: 12618761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
    Gupta S; Zhang J; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers.
    Srirangalingam U; Walker L; Khoo B; MacDonald F; Gardner D; Wilkin TJ; Skelly RH; George E; Spooner D; Monson JP; Grossman AB; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):587-96. PubMed ID: 18419787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas.
    Lee JP; Hung YP; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
    Histopathology; 2017 Oct; 71(4):503-510. PubMed ID: 28464318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.